Eli Lilly and Company rocketed back to growth in the second quarter of 2023 after multiple quarters in which revenues declined, as the company’s type 2 diabetes, oncology and immunology franchises carried sales back into the black and pressure from loss of exclusivity and COVID-19 lightened. Meanwhile, the drug maker is gearing up for potential approvals and launches of drugs for Alzheimer’s disease and obesity while progressing on the launch of its BTK inhibitor in non-Hodgkin’s lymphoma that won approval earlier this year.
The Indianapolis-based firm announced its second quarter earnings on 8 August, reporting revenues of $8.31bn, up from $6.49bn in the second quarter of 2022, when sales fell by 4%. (Also see "As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan" - Scrip, 4 August, 2022.) The 28% sales growth also contrasts with the 11% sales decline that Lilly reported in the first quarter and the 10% decline that it reported in the fourth quarter of 2022. (Also see "Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market" - Scrip, 27 April, 2023
